25 XP   0   0   10

Cerevel Therapeutics Holdings Inc
Buy, Hold or Sell?

Let's analyse Cerevel together

PenkeI guess you are interested in Cerevel Therapeutics Holdings Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cerevel Therapeutics Holdings Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cerevel Therapeutics Holdings Inc

I send you an email if I find something interesting about Cerevel Therapeutics Holdings Inc.

Quick analysis of Cerevel (30 sec.)










What can you expect buying and holding a share of Cerevel? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.71
Expected worth in 1 year
$4.55
How sure are you?
30.8%

+ What do you gain per year?

Total Gains per Share
$0.84
Return On Investment
2.0%

For what price can you sell your share?

Current Price per Share
$41.60
Expected price per share
$35.98 - $43.59
How sure are you?
50%

1. Valuation of Cerevel (5 min.)




Live pricePrice per Share (EOD)

$41.60

Intrinsic Value Per Share

$-24.08 - $-28.34

Total Value Per Share

$-20.37 - $-24.63

2. Growth of Cerevel (5 min.)




Is Cerevel growing?

Current yearPrevious yearGrowGrow %
How rich?$673.7m$524.7m-$92.4m-21.4%

How much money is Cerevel making?

Current yearPrevious yearGrowGrow %
Making money-$108.2m-$87.4m-$20.8m-19.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cerevel (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#81 / 1019

Most Revenue
#905 / 1019

Most Profit
#978 / 1019

Most Efficient
#437 / 1019

What can you expect buying and holding a share of Cerevel? (5 min.)

Welcome investor! Cerevel's management wants to use your money to grow the business. In return you get a share of Cerevel.

What can you expect buying and holding a share of Cerevel?

First you should know what it really means to hold a share of Cerevel. And how you can make/lose money.

Speculation

The Price per Share of Cerevel is $41.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cerevel.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cerevel, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.71. Based on the TTM, the Book Value Change Per Share is $0.21 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cerevel.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.73-1.8%-0.60-1.4%-0.48-1.2%-0.40-1.0%-0.26-0.6%
Usd Book Value Change Per Share2.215.3%0.210.5%-0.08-0.2%0.230.6%0.140.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.215.3%0.210.5%-0.08-0.2%0.230.6%0.140.3%
Usd Price Per Share42.40-30.10-30.31-23.12-14.23-
Price to Earnings Ratio-14.51--12.48--16.20--14.57--8.97-
Price-to-Total Gains Ratio19.21--38.11--54.16--112.32--112.32-
Price to Book Ratio11.43-13.17-10.57--149.72--92.13-
Price-to-Total Gains Ratio19.21--38.11--54.16--112.32--112.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share41.6
Number of shares24
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.210.23
Usd Total Gains Per Share0.210.23
Gains per Quarter (24 shares)5.045.56
Gains per Year (24 shares)20.1622.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10201002212
20403004434
30605006756
40817008978
50101900111100
601211100133122
701411300156144
801611500178166
901811700200188
1002021900222210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.016.00.00.0%0.026.00.00.0%2.033.00.05.7%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%4.010.02.025.0%8.016.02.030.8%10.022.03.028.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.016.00.0%0.00.026.00.0%1.00.034.02.9%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%4.010.02.025.0%8.016.02.030.8%10.022.03.028.6%

Fundamentals of Cerevel

About Cerevel Therapeutics Holdings Inc

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 03:56:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cerevel Therapeutics Holdings Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cerevel earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cerevel to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cerevel Therapeutics Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-397.7%+397.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y--436.8%+436.8%
10Y-397.7%-599.3%+201.6%
1.1.2. Return on Assets

Shows how efficient Cerevel is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cerevel to the Biotechnology industry mean.
  • -10.7% Return on Assets means that Cerevel generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cerevel Therapeutics Holdings Inc:

  • The MRQ is -10.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.7%TTM-11.2%+0.5%
TTM-11.2%YOY-10.9%-0.2%
TTM-11.2%5Y-86.4%+75.2%
5Y-86.4%10Y-93.4%+7.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.7%-13.6%+2.9%
TTM-11.2%-12.9%+1.7%
YOY-10.9%-11.9%+1.0%
5Y-86.4%-14.2%-72.2%
10Y-93.4%-16.2%-77.2%
1.1.3. Return on Equity

Shows how efficient Cerevel is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cerevel to the Biotechnology industry mean.
  • -19.7% Return on Equity means Cerevel generated $-0.20 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cerevel Therapeutics Holdings Inc:

  • The MRQ is -19.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -26.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.7%TTM-26.9%+7.2%
TTM-26.9%YOY-16.7%-10.2%
TTM-26.9%5Y-416.6%+389.8%
5Y-416.6%10Y-290.0%-126.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.7%-17.0%-2.7%
TTM-26.9%-16.1%-10.8%
YOY-16.7%-15.4%-1.3%
5Y-416.6%-20.0%-396.6%
10Y-290.0%-21.1%-268.9%

1.2. Operating Efficiency of Cerevel Therapeutics Holdings Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cerevel is operating .

  • Measures how much profit Cerevel makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cerevel to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cerevel Therapeutics Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-397.2%+397.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y--475.2%+475.2%
10Y-397.2%-624.7%+227.5%
1.2.2. Operating Ratio

Measures how efficient Cerevel is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cerevel Therapeutics Holdings Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y4.887-4.887
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y-5.675-5.675
10Y4.8877.857-2.970

1.3. Liquidity of Cerevel Therapeutics Holdings Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cerevel is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.92 means the company has $10.92 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cerevel Therapeutics Holdings Inc:

  • The MRQ is 10.924. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.117. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.924TTM11.117-0.193
TTM11.117YOY13.578-2.461
TTM11.1175Y10.810+0.307
5Y10.81010Y8.116+2.694
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.9243.930+6.994
TTM11.1174.251+6.866
YOY13.5785.436+8.142
5Y10.8106.045+4.765
10Y8.1166.363+1.753
1.3.2. Quick Ratio

Measures if Cerevel is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cerevel to the Biotechnology industry mean.
  • A Quick Ratio of 17.04 means the company can pay off $17.04 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cerevel Therapeutics Holdings Inc:

  • The MRQ is 17.040. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 19.002. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ17.040TTM19.002-1.961
TTM19.002YOY24.015-5.013
TTM19.0025Y15.659+3.343
5Y15.65910Y11.799+3.859
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.0403.629+13.411
TTM19.0024.065+14.937
YOY24.0155.397+18.618
5Y15.6595.993+9.666
10Y11.7996.277+5.522

1.4. Solvency of Cerevel Therapeutics Holdings Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cerevel assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cerevel to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.46 means that Cerevel assets are financed with 45.8% credit (debt) and the remaining percentage (100% - 45.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cerevel Therapeutics Holdings Inc:

  • The MRQ is 0.458. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.568. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.458TTM0.568-0.109
TTM0.568YOY0.334+0.234
TTM0.5685Y0.444+0.124
5Y0.44410Y0.658-0.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4580.332+0.126
TTM0.5680.334+0.234
YOY0.3340.268+0.066
5Y0.4440.366+0.078
10Y0.6580.390+0.268
1.4.2. Debt to Equity Ratio

Measures if Cerevel is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cerevel to the Biotechnology industry mean.
  • A Debt to Equity ratio of 84.5% means that company has $0.85 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cerevel Therapeutics Holdings Inc:

  • The MRQ is 0.845. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.391. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ0.845TTM1.391-0.545
TTM1.391YOY0.567+0.824
TTM1.3915Y1.108+0.283
5Y1.10810Y1.249-0.141
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8450.381+0.464
TTM1.3910.390+1.001
YOY0.5670.334+0.233
5Y1.1080.434+0.674
10Y1.2490.466+0.783

2. Market Valuation of Cerevel Therapeutics Holdings Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cerevel generates.

  • Above 15 is considered overpriced but always compare Cerevel to the Biotechnology industry mean.
  • A PE ratio of -14.51 means the investor is paying $-14.51 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cerevel Therapeutics Holdings Inc:

  • The EOD is -14.235. Based on the earnings, the company is expensive. -2
  • The MRQ is -14.509. Based on the earnings, the company is expensive. -2
  • The TTM is -12.477. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.235MRQ-14.509+0.274
MRQ-14.509TTM-12.477-2.032
TTM-12.477YOY-16.200+3.723
TTM-12.4775Y-14.569+2.093
5Y-14.56910Y-8.966-5.604
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.235-2.315-11.920
MRQ-14.509-2.560-11.949
TTM-12.477-2.664-9.813
YOY-16.200-4.122-12.078
5Y-14.569-6.258-8.311
10Y-8.966-6.108-2.858
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cerevel Therapeutics Holdings Inc:

  • The EOD is -19.206. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -19.576. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.731. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.206MRQ-19.576+0.369
MRQ-19.576TTM-15.731-3.844
TTM-15.731YOY-18.843+3.112
TTM-15.7315Y-16.678+0.947
5Y-16.67810Y-10.263-6.415
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-19.206-3.067-16.139
MRQ-19.576-3.251-16.325
TTM-15.731-3.545-12.186
YOY-18.843-5.595-13.248
5Y-16.678-8.315-8.363
10Y-10.263-8.708-1.555
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cerevel is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 11.43 means the investor is paying $11.43 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cerevel Therapeutics Holdings Inc:

  • The EOD is 11.211. Based on the equity, the company is expensive. -2
  • The MRQ is 11.427. Based on the equity, the company is expensive. -2
  • The TTM is 13.169. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD11.211MRQ11.427-0.216
MRQ11.427TTM13.169-1.742
TTM13.169YOY10.571+2.598
TTM13.1695Y-149.718+162.887
5Y-149.71810Y-92.134-57.584
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD11.2111.905+9.306
MRQ11.4272.111+9.316
TTM13.1692.095+11.074
YOY10.5712.836+7.735
5Y-149.7183.443-153.161
10Y-92.1343.794-95.928
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cerevel Therapeutics Holdings Inc.

3.1. Institutions holding Cerevel Therapeutics Holdings Inc

Institutions are holding 86.48% of the shares of Cerevel Therapeutics Holdings Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Bain Capital Investors LLC36.17260.3856567978154800529.1031
2023-12-31Perceptive Advisors LLC6.038910.3778109651938768088.6913
2023-12-31FMR Inc5.33760.03169691851-13931293-58.9731
2023-12-31venBio Select Advisor LLC4.16114.42575555556600000690.6981
2023-12-31Vanguard Group Inc4.06160.00687374970100359415.7516
2023-12-31BlackRock Inc3.31960.00656027525103649920.7673
2023-12-31State Street Corporation1.57060.00592851819-48516-1.6728
2023-12-31Fidelity International Ltd1.52330.1232276600027660000
2023-12-31Rock Springs Capital Management LP1.47282.791326742451451295.7383
2023-12-31Paradigm Biocapital Advisors LP1.28354.62632330508-202464-7.9931
2023-12-31Balyasny Asset Management LLC1.06910.1546194121519114196415.0188
2023-12-31Geode Capital Management, LLC0.98540.0079178930235002524.3195
2023-12-31Eckert Corp0.90553.5746164410016441000
2023-12-31Baker Bros Advisors LP0.88120.7719160000016000000
2023-12-31AllianceBernstein L.P.0.62380.0185113264010421001150.983
2023-12-31Millennium Management LLC0.61190.02041111112-1018701-47.8305
2023-12-31Pentwater Capital Management LP0.60580.5229110000011000000
2023-12-31Goldman Sachs Group Inc0.58680.00411065514741015228.3566
2023-12-31Magnetar Financial LLC0.56091.0963101842810184280
2023-12-31Cnh Partners, LLC0.51431.59919337649337640
Total 72.285790.5497131253522+13047959+9.9%

3.2. Funds holding Cerevel Therapeutics Holdings Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.26080.00612289239-5800-0.2527
2024-02-29Vanguard Small Cap Index1.02350.05421858522168610.9155
2024-03-28SPDR® S&P Biotech ETF1.02011.03681852184233601.2773
2024-03-28iShares Russell 2000 ETF0.96710.1134175606676870.4397
2024-02-29Fidelity Growth Compy Commingled Pl O0.86720.08231574571-711900-31.1353
2023-12-31Fidelity Canadian Large Cap Sr B0.74351.0707135000013500000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.7210.052613091659990.0764
2024-02-29Fidelity Growth Company Fund0.63820.07961158812-419000-26.5558
2024-02-29Vanguard Small Cap Growth Index Inv0.57330.12231040968136181.3255
2023-12-31American Funds SMALLCAP World A0.47570.05098636868636860
2024-01-31Fidelity Small Cap Index0.38880.1193706058110551.5906
2024-02-29Fidelity Canadian Large Cp Mlt Ast Bs O0.38551.2133700000400006.0606
2024-03-28iShares Russell 2000 Growth ETF0.34220.2254621428-723-0.1162
2023-12-31The Merger Fund A0.30890.88095609705609700
2024-02-29Fidelity Extended Market Index0.2740.053249756919180.387
2023-12-31Eventide Healthcare & Life Sciences I0.26991.246449000000
2023-12-31T. Rowe Price Integrated US Sm Gr Eq0.26890.2656488200138002.9089
2023-12-31AQR Diversified Arbitrage I0.2621.11324756914756910
2024-02-29Arbitrage R0.26081.95634734674734670
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.23360.0416424074118002.8622
Total 11.2859.784120490670+2727489+13.3%

3.3. Insider Transactions

Insiders are holding 15.325% of the shares of Cerevel Therapeutics Holdings Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-04N Anthony ColesSELL5000041.01
2024-02-29N Anthony ColesSELL5000041.16
2024-02-07John RengerSELL216141.54
2024-02-07N Anthony ColesSELL250641.54
2023-12-26Ramiro SanchezSELL1000042.47
2023-12-22Kenneth DipietroSELL800041.45
2023-12-20Mark BodenraderSELL788941.42
2023-12-20Susan AltschullerSELL1380841.42
2023-12-07Scott AkamineSELL1000041.37
2023-12-05Scott AkamineSELL750035
2023-11-08N Anthony ColesSELL10025.16
2023-11-03N Anthony ColesSELL6140125.43
2023-10-16Bain Capital Investors LlcBUY548005222.81
2023-10-16Perceptive Advisors LlcBUY87680822.81
2023-09-07N Anthony ColesSELL5000024.07
2023-08-04Paul D BurgessBUY2188022.93
2023-08-03Ronald C Renaud JrBUY8385723.96
2023-07-11N Anthony ColesSELL5000030.03
2023-06-15Marijn E DekkersSELL20000034.43
2023-06-02Mark BodenraderSELL189532.95

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cerevel Therapeutics Holdings Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.2070.210+951%-0.079+104%0.231+854%0.137+1508%
Book Value Per Share--3.7112.380+56%2.890+28%2.084+78%1.303+185%
Current Ratio--10.92411.117-2%13.578-20%10.810+1%8.116+35%
Debt To Asset Ratio--0.4580.568-19%0.334+37%0.444+3%0.658-30%
Debt To Equity Ratio--0.8451.391-39%0.567+49%1.108-24%1.249-32%
Dividend Per Share----0%-0%-0%-0%
Eps---0.731-0.596-18%-0.484-34%-0.399-45%-0.257-65%
Free Cash Flow Per Share---0.541-0.477-12%-0.409-24%-0.334-38%-0.216-60%
Free Cash Flow To Equity Per Share--2.2580.279+710%0.449+403%0.367+516%0.223+915%
Gross Profit Margin--1.0111.003+1%1.000+1%1.001+1%1.024-1%
Intrinsic Value_10Y_max---28.343--------
Intrinsic Value_10Y_min---24.081--------
Intrinsic Value_1Y_max---1.720--------
Intrinsic Value_1Y_min---1.689--------
Intrinsic Value_3Y_max---6.022--------
Intrinsic Value_3Y_min---5.732--------
Intrinsic Value_5Y_max---11.353--------
Intrinsic Value_5Y_min---10.464--------
Market Cap7553561600.000-2%7698822400.0005465891540.000+41%5504022500.000+40%4198491060.000+83%2583686806.154+198%
Net Profit Margin----0%-0%-0%-3.9770%
Operating Margin----0%-0%-0%-3.9720%
Operating Ratio----0%-0%-0%4.887-100%
Pb Ratio11.211-2%11.42713.169-13%10.571+8%-149.718+1410%-92.134+906%
Pe Ratio-14.235+2%-14.509-12.477-14%-16.200+12%-14.569+0%-8.966-38%
Price Per Share41.600-2%42.40030.103+41%30.313+40%23.123+83%14.229+198%
Price To Free Cash Flow Ratio-19.206+2%-19.576-15.731-20%-18.843-4%-16.678-15%-10.263-48%
Price To Total Gains Ratio18.847-2%19.209-38.114+298%-54.156+382%-112.325+685%-112.325+685%
Quick Ratio--17.04019.002-10%24.015-29%15.659+9%11.799+44%
Return On Assets---0.107-0.112+5%-0.109+3%-0.864+710%-0.934+776%
Return On Equity---0.197-0.269+37%-0.167-15%-4.166+2016%-2.900+1373%
Total Gains Per Share--2.2070.210+951%-0.079+104%0.231+854%0.137+1508%
Usd Book Value--673745000.000432229000.000+56%524728250.000+28%378488750.000+78%236636769.231+185%
Usd Book Value Change Per Share--2.2070.210+951%-0.079+104%0.231+854%0.137+1508%
Usd Book Value Per Share--3.7112.380+56%2.890+28%2.084+78%1.303+185%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.731-0.596-18%-0.484-34%-0.399-45%-0.257-65%
Usd Free Cash Flow---98322000.000-86527250.000-12%-74285250.000-24%-60562062.500-38%-39306269.231-60%
Usd Free Cash Flow Per Share---0.541-0.477-12%-0.409-24%-0.334-38%-0.216-60%
Usd Free Cash Flow To Equity Per Share--2.2580.279+710%0.449+403%0.367+516%0.223+915%
Usd Market Cap7553561600.000-2%7698822400.0005465891540.000+41%5504022500.000+40%4198491060.000+83%2583686806.154+198%
Usd Price Per Share41.600-2%42.40030.103+41%30.313+40%23.123+83%14.229+198%
Usd Profit---132660000.000-108210500.000-18%-87403250.000-34%-72495687.500-45%-46737653.846-65%
Usd Revenue----0%-0%-0%271884.615-100%
Usd Total Gains Per Share--2.2070.210+951%-0.079+104%0.231+854%0.137+1508%
 EOD+2 -6MRQTTM+21 -9YOY+16 -145Y+20 -1010Y+22 -10

4.2. Fundamental Score

Let's check the fundamental score of Cerevel Therapeutics Holdings Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-14.235
Price to Book Ratio (EOD)Between0-111.211
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than117.040
Current Ratio (MRQ)Greater than110.924
Debt to Asset Ratio (MRQ)Less than10.458
Debt to Equity Ratio (MRQ)Less than10.845
Return on Equity (MRQ)Greater than0.15-0.197
Return on Assets (MRQ)Greater than0.05-0.107
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cerevel Therapeutics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.579
Ma 20Greater thanMa 5042.122
Ma 50Greater thanMa 10041.922
Ma 100Greater thanMa 20040.548
OpenGreater thanClose41.470
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Debt  230,151-17,624212,527-22,307190,22019,665209,885-720,072-510,187



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,243,298
Total Liabilities569,553
Total Stockholder Equity673,745
 As reported
Total Liabilities 569,553
Total Stockholder Equity+ 673,745
Total Assets = 1,243,298

Assets

Total Assets1,243,298
Total Current Assets1,006,938
Long-term Assets236,360
Total Current Assets
Cash And Cash Equivalents 990,965
Short-term Investments 574,500
Net Receivables 5,291
Total Current Assets  (as reported)1,006,938
Total Current Assets  (calculated)1,570,756
+/- 563,818
Long-term Assets
Property Plant Equipment 45,772
Long Term Investments 185,199
Long-term Assets Other 3,429
Long-term Assets  (as reported)236,360
Long-term Assets  (calculated)234,400
+/- 1,960

Liabilities & Shareholders' Equity

Total Current Liabilities92,179
Long-term Liabilities477,374
Total Stockholder Equity673,745
Total Current Liabilities
Short-term Debt 3,404
Accounts payable 11,863
Other Current Liabilities 76,912
Total Current Liabilities  (as reported)92,179
Total Current Liabilities  (calculated)92,179
+/-0
Long-term Liabilities
Long term Debt 337,424
Capital Lease Obligations Min Short Term Debt27,786
Long-term Liabilities Other 112,164
Long-term Liabilities  (as reported)477,374
Long-term Liabilities  (calculated)477,374
+/-0
Total Stockholder Equity
Common Stock18
Retained Earnings -1,400,597
Accumulated Other Comprehensive Income 1,771
Other Stockholders Equity 2,072,553
Total Stockholder Equity (as reported)673,745
Total Stockholder Equity (calculated)673,745
+/-0
Other
Capital Stock18
Cash and Short Term Investments 990,965
Common Stock Shares Outstanding 174,601
Liabilities and Stockholders Equity 1,243,298
Net Debt -510,187
Net Invested Capital 1,011,169
Net Working Capital 914,759
Property Plant and Equipment Gross 58,338
Short Long Term Debt Total 480,778



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
90,592
75,013
75,013
69,247
62,278
52,900
44,857
4,742
30,944
24,885
37,778
3,095
26,558
18,462
13,411
1,356
6,833
8,642
6,743
0
0
67,037
445,273
408,104
391,004
733,480
688,919
618,552
596,657
1,093,712
1,017,822
930,345
894,353
821,962
1,243,298
1,243,298821,962894,353930,3451,017,8221,093,712596,657618,552688,919733,480391,004408,104445,27367,037006,7438,6426,8331,35613,41118,46226,5583,09537,77824,88530,9444,74244,85752,90062,27869,24775,01375,01390,592
   > Total Current Assets 
82,219
69,746
69,746
57,568
55,458
47,552
39,834
32,436
26,268
20,412
32,467
29,329
23,689
15,725
10,944
9,766
5,511
7,253
5,405
54,254
21,894
15,884
390,560
349,811
331,782
675,029
578,017
553,550
540,141
998,658
905,651
840,782
751,673
687,786
1,006,938
1,006,938687,786751,673840,782905,651998,658540,141553,550578,017675,029331,782349,811390,56015,88421,89454,2545,4057,2535,5119,76610,94415,72523,68929,32932,46720,41226,26832,43639,83447,55255,45857,56869,74669,74682,219
       Cash And Cash Equivalents 
79,271
67,720
67,720
21,069
14,378
15,467
18,821
8,881
7,314
5,448
5,890
3,423
4,254
4,782
5,429
8,095
3,438
5,778
4,152
0
0
12,808
383,623
343,287
327,060
669,676
193,018
91,764
138,218
248,600
136,521
153,816
175,763
155,721
990,965
990,965155,721175,763153,816136,521248,600138,21891,764193,018669,676327,060343,287383,62312,808004,1525,7783,4388,0955,4294,7824,2543,4235,8905,4487,3148,88118,82115,46714,37821,06967,72067,72079,271
       Short-term Investments 
3,000
0
33,565
33,565
37,636
29,364
18,554
21,630
17,127
12,883
24,393
24,579
17,343
9,852
3,653
60
60
0
0
0
0
0
0
0
0
0
372,670
451,180
392,990
741,318
755,509
673,171
560,663
521,161
574,500
574,500521,161560,663673,171755,509741,318392,990451,180372,67000000000060603,6539,85217,34324,57924,39312,88317,12721,63018,55429,36437,63633,56533,56503,000
       Net Receivables 
880
579
579
765
1,488
697
848
957
901
761
460
370
321
333
661
577
848
813
384
0
0
0
0
0
0
0
729
602
981
824
2,046
3,202
4,135
3,409
5,291
5,2913,4094,1353,2022,04682498160272900000003848138485776613333213704607619019578486971,488765579579880
       Other Current Assets 
-932
0
1,447
1,328
902
885
1,259
948
926
1,320
1,724
873
981
633
1,201
1,094
1,165
662
869
169
149
3,076
6,937
162
125
96
12,329
292
1,101
338
13,621
13,795
15,247
10,904
10,682
10,68210,90415,24713,79513,6213381,10129212,329961251626,9373,0761491698696621,1651,0941,2016339818731,7241,3209269481,2598859021,3281,4470-932
   > Long-term Assets 
8,373
0
5,267
11,679
6,820
5,348
5,023
-27,694
4,676
4,473
5,311
-26,234
2,869
2,737
2,467
-8,410
1,322
1,389
1,338
0
0
51,153
54,713
58,293
59,222
58,451
110,902
65,002
56,516
95,054
112,171
89,563
142,680
134,176
236,360
236,360134,176142,68089,563112,17195,05456,51665,002110,90258,45159,22258,29354,71351,153001,3381,3891,322-8,4102,4672,7372,869-26,2345,3114,4734,676-27,6945,0235,3486,82011,6795,26708,373
       Property Plant Equipment 
5,256
5,168
5,168
5,756
5,559
5,241
4,915
4,633
4,632
4,429
2,966
2,996
2,767
2,639
2,369
1,258
1,196
1,214
1,158
32,691
34,977
41,347
48,624
51,784
51,920
51,980
51,700
52,663
51,887
50,527
49,287
48,440
48,262
47,193
45,772
45,77247,19348,26248,44049,28750,52751,88752,66351,70051,98051,92051,78448,62441,34734,97732,6911,1581,2141,1961,2582,3692,6392,7672,9962,9664,4294,6324,6334,9155,2415,5595,7565,1685,1685,256
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
52,269
7,928
0
39,863
58,126
36,048
88,637
81,340
185,199
185,19981,34088,63736,04858,12639,86307,92852,26900000000000000000000000000
       Long-term Assets Other 
3,117
99
99
-87,828
105
-29,257
-18,446
-53,957
-17,083
-12,839
-22,048
-53,809
-17,241
-9,754
-3,555
-9,668
126
175
180
0
0
9,806
6,089
6,509
7,302
6,471
6,933
4,411
2,762
4,664
4,758
5,075
5,781
5,643
3,429
3,4295,6435,7815,0754,7584,6642,7624,4116,9336,4717,3026,5096,0899,80600180175126-9,668-3,555-9,754-17,241-53,809-22,048-12,839-17,083-53,957-18,446-29,257105-87,82899993,117
> Total Liabilities 
14,038
6,481
6,481
6,686
5,889
4,894
5,236
4,172
5,108
5,392
4,286
4,815
4,332
3,989
4,043
6,909
5,651
6,110
5,500
0
0
67,784
60,753
68,068
97,117
104,400
110,190
97,053
143,843
490,350
496,584
498,636
543,853
549,000
569,553
569,553549,000543,853498,636496,584490,350143,84397,053110,190104,40097,11768,06860,75367,784005,5006,1105,6516,9094,0433,9894,3324,8154,2865,3925,1084,1725,2364,8945,8896,6866,4816,48114,038
   > Total Current Liabilities 
11,172
6,145
6,145
6,342
5,724
4,768
5,009
3,997
4,960
5,264
4,176
4,722
4,262
3,924
3,982
5,222
4,360
2,620
2,745
22,915
22,770
29,209
29,548
34,151
29,257
30,800
42,538
35,318
56,743
60,020
72,564
62,957
65,560
78,838
92,179
92,17978,83865,56062,95772,56460,02056,74335,31842,53830,80029,25734,15129,54829,20922,77022,9152,7452,6204,3605,2223,9823,9244,2624,7224,1765,2644,9603,9975,0094,7685,7246,3426,1456,14511,172
       Short-term Debt 
2,997
25
25
134
65
103
84
0
0
0
0
55
55
44
0
0
389
439
466
0
0
2,206
2,036
2,139
2,236
2,335
2,437
2,563
2,672
2,785
2,899
3,028
3,150
3,276
3,404
3,4043,2763,1503,0282,8992,7852,6722,5632,4372,3352,2362,1392,0362,20600466439389004455550000841036513425252,997
       Accounts payable 
7,006
0
5,285
5,476
5,314
4,442
4,899
3,825
4,745
4,804
3,943
4,278
3,743
3,040
3,157
4,402
3,826
1,994
2,361
8,307
8,878
4,822
4,993
7,755
4,986
5,445
11,298
8,183
11,008
14,971
10,061
7,315
9,389
11,541
11,863
11,86311,5419,3897,31510,06114,97111,0088,18311,2985,4454,9867,7554,9934,8228,8788,3072,3611,9943,8264,4023,1573,0403,7434,2783,9434,8044,7453,8254,8994,4425,3145,4765,28507,006
       Other Current Liabilities 
1,169
0
835
31
345
223
26
172
215
460
233
88
464
840
825
820
-371
-421
-448
2,095
1,961
339
273
155
332
427
375
24,572
43,063
42,264
59,604
52,614
53,021
64,021
76,912
76,91264,02153,02152,61459,60442,26443,06324,5723754273321552733391,9612,095-448-421-37182082584046488233460215172262233453183501,169
   > Long-term Liabilities 
2,866
0
336
344
165
126
227
3,825
4,833
4,888
4,022
4,278
125
109
3,218
4,402
104
94
86
0
0
38,575
31,205
33,917
67,860
73,600
67,652
61,735
87,100
430,330
424,020
435,679
478,293
470,162
477,374
477,374470,162478,293435,679424,020430,33087,10061,73567,65273,60067,86033,91731,20538,5750086941044,4023,2181091254,2784,0224,8884,8333,82522712616534433602,866
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
335,006
335,482
335,962
0
0
0
000335,962335,482335,00600000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,998
9,783
18,219
236
965
34,953
236
33,542
2
2
2
0
0
0
0
0
0000022233,54223634,95396523618,2199,78317,9980000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,466
424
5,052
0
461
635
0
485
465
465
307
286
0
287
0
0
002870286307465465485063546105,0524242,4660000000000000000000
> Total Stockholder Equity
76,554
0
68,532
62,561
56,389
48,006
39,621
33,006
25,836
19,493
33,492
27,609
22,226
14,473
9,368
4,213
1,182
2,532
1,243
0
0
-747
384,520
340,036
293,887
629,080
578,729
521,499
452,814
603,362
521,238
431,709
350,500
272,962
673,745
673,745272,962350,500431,709521,238603,362452,814521,499578,729629,080293,887340,036384,520-747001,2432,5321,1824,2139,36814,47322,22627,60933,49219,49325,83633,00639,62148,00656,38962,56168,532076,554
   Common Stock
0
0
0
245
0
0
0
248
309,212
310,154
331,841
482
0
0
333,886
1,631
0
3,443
2,712
0
0
137,591
13
13
13
15
15
15
15
16
16
16
16
16
18
18161616161615151515131313137,591002,7123,44301,631333,88600482331,841310,154309,212248000245000
   Retained Earnings -1,400,597-1,267,937-1,171,576-1,072,041-967,755-874,947-775,009-684,538-616,244-557,189-495,130-441,891-390,910-3,124-324,223-297,506-338,037-336,532-335,480-335,4800-317,985-309,878-309,8780000-267,255-257,933-248,967-242,073-235,451-235,451-227,035
   Accumulated Other Comprehensive Income 
-79
-148
-148
-283
-384
-718
-572
-696
-587
-647
-608
-595
-621
-857
-631
762
792
887
794
0
0
0
0
-92
0
-533
-986
-1,334
7,988
5,194
3,097
3,688
1,142
1,682
1,771
1,7711,6821,1423,6883,0975,1947,988-1,334-986-5330-920000794887792762-631-857-621-595-608-647-587-696-572-718-384-283-148-148-79
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
775,417
781,914
789,004
1,186,787
1,195,944
1,207,356
1,219,820
1,473,099
1,485,880
1,500,046
0
0
0
0001,500,0461,485,8801,473,0991,219,8201,207,3561,195,9441,186,787789,004781,914775,4170000000000000000000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
303,668
0
304,131
304,672
305,740
306,657
307,448
33,454
-282,789
-290,014
-297,741
27,722
332,725
333,315
-323,887
1,820
335,870
334,734
335,774
0
0
-135,214
775,417
781,914
789,004
1,186,787
1,195,944
1,207,356
1,219,820
1,473,099
1,485,880
1,500,046
1,520,918
1,539,201
2,072,553
2,072,5531,539,2011,520,9181,500,0461,485,8801,473,0991,219,8201,207,3561,195,9441,186,787789,004781,914775,417-135,21400335,774334,734335,8701,820-323,887333,315332,72527,722-297,741-290,014-282,78933,454307,448306,657305,740304,672304,1310303,668



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-5,627
Gross Profit-5,627-5,627
 
Operating Income (+$)
Gross Profit-5,627
Operating Expense-441,638
Operating Income-447,265-447,265
 
Operating Expense (+$)
Research Development334,641
Selling General Administrative112,624
Selling And Marketing Expenses5,627
Operating Expense441,638452,892
 
Net Interest Income (+$)
Interest Income43,865
Interest Expense-10,567
Other Finance Cost-6,480
Net Interest Income26,818
 
Pretax Income (+$)
Operating Income-447,265
Net Interest Income26,818
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-432,339-462,191
EBIT - interestExpense = -457,832
-432,339
-422,275
Interest Expense10,567
Earnings Before Interest and Taxes (EBIT)-447,265-421,772
Earnings Before Interest and Taxes (EBITDA)-441,638
 
After tax Income (+$)
Income Before Tax-432,339
Tax Provision-503
Net Income From Continuing Ops-432,842-432,842
Net Income-432,842
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses447,265
Total Other Income/Expenses Net14,926-26,818
 

Technical Analysis of Cerevel
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cerevel. The general trend of Cerevel is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cerevel's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cerevel Therapeutics Holdings Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 42.10 < 42.80 < 43.59.

The bearish price targets are: 40.80 > 40.66 > 35.98.

Tweet this
Cerevel Therapeutics Holdings Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cerevel Therapeutics Holdings Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cerevel Therapeutics Holdings Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cerevel Therapeutics Holdings Inc. The current macd is -0.06714078.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cerevel price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cerevel. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cerevel price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cerevel Therapeutics Holdings Inc Daily Moving Average Convergence/Divergence (MACD) ChartCerevel Therapeutics Holdings Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cerevel Therapeutics Holdings Inc. The current adx is 20.02.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cerevel shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Cerevel Therapeutics Holdings Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cerevel Therapeutics Holdings Inc. The current sar is 42.13.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cerevel Therapeutics Holdings Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cerevel Therapeutics Holdings Inc. The current rsi is 40.58. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Cerevel Therapeutics Holdings Inc Daily Relative Strength Index (RSI) ChartCerevel Therapeutics Holdings Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cerevel Therapeutics Holdings Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cerevel price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cerevel Therapeutics Holdings Inc Daily Stochastic Oscillator ChartCerevel Therapeutics Holdings Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cerevel Therapeutics Holdings Inc. The current cci is -179.36858775.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Cerevel Therapeutics Holdings Inc Daily Commodity Channel Index (CCI) ChartCerevel Therapeutics Holdings Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cerevel Therapeutics Holdings Inc. The current cmo is -29.11063271.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cerevel Therapeutics Holdings Inc Daily Chande Momentum Oscillator (CMO) ChartCerevel Therapeutics Holdings Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cerevel Therapeutics Holdings Inc. The current willr is -70.03393747.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cerevel is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cerevel Therapeutics Holdings Inc Daily Williams %R ChartCerevel Therapeutics Holdings Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cerevel Therapeutics Holdings Inc.

Cerevel Therapeutics Holdings Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cerevel Therapeutics Holdings Inc. The current atr is 0.35129627.

Cerevel Therapeutics Holdings Inc Daily Average True Range (ATR) ChartCerevel Therapeutics Holdings Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cerevel Therapeutics Holdings Inc. The current obv is 62,040,284.

Cerevel Therapeutics Holdings Inc Daily On-Balance Volume (OBV) ChartCerevel Therapeutics Holdings Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cerevel Therapeutics Holdings Inc. The current mfi is 28.53.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cerevel Therapeutics Holdings Inc Daily Money Flow Index (MFI) ChartCerevel Therapeutics Holdings Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cerevel Therapeutics Holdings Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Cerevel Therapeutics Holdings Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cerevel Therapeutics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.579
Ma 20Greater thanMa 5042.122
Ma 50Greater thanMa 10041.922
Ma 100Greater thanMa 20040.548
OpenGreater thanClose41.470
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cerevel with someone you think should read this too:
  • Are you bullish or bearish on Cerevel? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cerevel? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cerevel Therapeutics Holdings Inc

I send you an email if I find something interesting about Cerevel Therapeutics Holdings Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cerevel Therapeutics Holdings Inc.

Receive notifications about Cerevel Therapeutics Holdings Inc in your mailbox!